Quarterly Updates30 May 2026, 09:01 pm
Kabra Drugs FY26 Total Income Up 14,463.06% YoY to ₹93.23 Cr
AI Summary
Kabra Drugs Ltd reported exceptional FY26 financial results, with total income reaching ₹93.23 crore, a 14,463.06% YoY increase. The company's EBITDA and PAT turned positive. In Q4 FY26, total income rose to ₹35.52 crore, a 5,448.13% YoY growth. EBITDA grew by 264.83% YoY to ₹1.45 crore, and PAT increased by 170.15% YoY to ₹1.06 crore. The company is expanding its pharmaceutical manufacturing and marketing, exploring AI-led defence technologies, and establishing an AI & Defence Technology R&D facility in Chennai.
Key Highlights
- FY26 total income surged to ₹93.23 crore, up 14,463.06% YoY.
- EBITDA and PAT turned positive in FY26, reaching ₹5.82 crore and ₹4.96 crore respectively.
- Q4 FY26 total income grew by 5,448.13% YoY to ₹35.52 crore.
- Company to expand pharmaceutical manufacturing and marketing across South India.
- Kabra Drugs to explore AI-led defence technologies and establish an R&D facility.
Price Impact
More from KABRADG